Investigating how Rnd3 affects lung cancer spread
Official title: Molecular Mechanism of Rnd3 Regulation in Lung Cancer
Funded at Univ of Arkansas for Med Scis · NIH-11049050 · Data updated 2026-11-12
This study is looking at how a protein called Rnd3 affects the movement of lung cancer cells, with the goal of finding new ways to treat lung cancer, especially when it spreads to other parts of the body.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Univ of Arkansas for Med Scis NIH-funded |
| Lab location | 1 site (Little Rock, United States) |
| Project start | March 5, 2024 |
| Project end | December 31, 2028 |
| Funding year | 2025 |
| Award (this year) | $255,902 |
| NIH project number | 5P20GM152281-02 |
| Project ID | NIH-11049050 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with lung adenocarcinoma, particularly those with varying levels of Rnd3 expression.
✕Less likely to help
Patients with non-lung cancers or those whose cancer has not metastasized may not benefit from this research.
What this research studies
This research focuses on understanding the role of a protein called Rnd3 in the spread of lung cancer, particularly how it influences cancer cell movement and invasion. Researchers will examine how changes in Rnd3 levels can affect the behavior of lung cancer cells, using laboratory techniques to analyze cell migration and invasion. By uncovering the molecular mechanisms behind Rnd3's regulation, the study aims to identify new therapeutic strategies for treating lung cancer, especially in cases where it has metastasized.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that improve survival rates for lung cancer patients by targeting the mechanisms of metastasis.
How similar studies have gone: Previous research has shown promising results in targeting molecular pathways in cancer treatment, suggesting that this approach could also yield significant insights.
Where this research is happening
-
Univ of Arkansas for Med Scis
Little Rock, United States Active
Researchers
- Principal investigator: Ryan, Katie — Univ of Arkansas for Med Scis
- Study coordinator: Ryan, Katie
Related research
Other NIH-funded projects on the same topics.
-
Blood-based markers to identify lung cancer risk in never-smokers
A researchers team at NYU School of Medicine is testing blood tests that might flag higher lung cancer risk in people who have never smoked, helping decide who might need screening.
-
Integrative Analysis of Lung Cancer Risk and Its Causes
A large, multi-part study at the University of New Mexico is exploring why lung cancer happens and how to better prevent and detect it.
-
Integrative Analysis of Lung Cancer Risk and Causes
A large NIH project is exploring how tobacco use, behavior, biology, and screening practices influence lung cancer risk and outcomes to help prevent and detect it earlier.
-
Digital health strategies to expand lung cancer screening in safety-net clinics
A funded project aims to help low-resource clinics increase the use of lung cancer screening for patients who smoke or are at risk.
-
Proteomics-guided matching of lung cancer tumors to preclinical models
This grant aims to improve how we match a patient’s lung cancer tumor to the right preclinical models using protein data.
-
Optimizing lung cancer care with smart tools for prevention, early detection, treatment, and survivorship
A U01 grant using AI and biomarkers to improve lung cancer prevention, screening, treatment, and survivorship care for people at risk or living with lung cancer.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.